Literature DB >> 9845532

A novel mutation in the D3 domain of von Willebrand factor markedly decreases its ability to bind factor VIII and affects its multimerization.

S Jorieux1, C Gaucher, J Goudemand, C Mazurier.   

Abstract

In type 2N von Willebrand disease (vWD), von Willebrand factor (vWF) is characterized by normal multimeric pattern, normal platelet-dependent function, but a markedly decreased affinity for factor VIII (FVIII). In this report, we describe the case of a vWD patient who has an abnormal vWF multimers distribution associated with a markedly decreased vWF ability to bind FVIII. Sequencing analysis of patient's vWF gene showed, at heterozygous state, a G-->A transition resulting in the substitution of Asn for Asp at position 116 of the mature vWF subunit and a C-->T transition, changing the codon for Arg 896 into a stop codon. His sister who has a subnormal vWF level, but a normal FVIII/vWF interaction, was found to be heterozygous for the Arg896ter mutation only. Recombinant vWF (rvWF) containing the candidate (Asn116) missense mutation was expressed in COS-7 cells. The expression level of Asn116rvWF was significantly decreased compared with wild-type rvWF. The multimeric pattern of Asn116rvWF was greatly impaired as shown by the decrease in high molecular weight forms. The FVIII binding ability of Asn116rvWF was dramatically decreased. These data show that the Asp116Asn substitution is the cause of both the defective FVIII/vWF interaction and the impaired multimeric pattern observed in the patient's vWF. The monoclonal antibody 31H3 against D' domain of vWF (epitope aa 66-76) that partially inhibits the FVIII binding and recognizes only nonreduced vWF, showed a decreased ability to bind Asn116rvWF when used as capture-antibody in enzyme-linked immunosorbent assay (ELISA). This result suggests that a potential conformation change in the D' domain is induced by the Asp116Asn substitution, which is localized in the D3 domain.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9845532

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  A common ancestor more than 10,000 years old for patients with R854Q-related type 2N von Willebrand's disease in Italy.

Authors:  Alessandra Casonato; Viviana Daidone; Giovanni Barbon; Elena Pontara; Irene Di Pasquale; Lisa Gallinaro; Letizia Marullo; Giorgio Bertorelle
Journal:  Haematologica       Date:  2012-08-08       Impact factor: 9.941

Review 2.  Molecular genetics of type 2 von Willebrand disease.

Authors:  Edith Fressinaud; Claudine Mazurier; Dominique Meyer
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

3.  The von Willebrand factor D'D3 assembly and structural principles for factor VIII binding and concatemer biogenesis.

Authors:  Xianchi Dong; Nina C Leksa; Ekta Seth Chhabra; Joseph W Arndt; Qi Lu; Kevin E Knockenhauer; Robert T Peters; Timothy A Springer
Journal:  Blood       Date:  2019-01-14       Impact factor: 22.113

4.  BMPER, a novel endothelial cell precursor-derived protein, antagonizes bone morphogenetic protein signaling and endothelial cell differentiation.

Authors:  Martin Moser; Olav Binder; Yaxu Wu; Julius Aitsebaomo; Rongqin Ren; Christoph Bode; Victoria L Bautch; Frank L Conlon; Cam Patterson
Journal:  Mol Cell Biol       Date:  2003-08       Impact factor: 4.272

5.  Cleavage of von Willebrand factor by granzyme M destroys its factor VIII binding capacity.

Authors:  Martine J Hollestelle; Ka Wai Lai; Marcel van Deuren; Peter J Lenting; Philip G de Groot; Tom Sprong; Niels Bovenschen
Journal:  PLoS One       Date:  2011-09-01       Impact factor: 3.240

6.  D' domain region Arg782-Cys799 of von Willebrand factor contributes to factor VIII binding.

Authors:  Małgorzata A Przeradzka; Josse van Galen; Eduard H T M Ebberink; Arie J Hoogendijk; Carmen van der Zwaan; Koen Mertens; Maartje van den Biggelaar; Alexander B Meijer
Journal:  Haematologica       Date:  2019-09-26       Impact factor: 9.941

Review 7.  Occlusive thrombosis in arteries.

Authors:  Dongjune Kim; Christopher Bresette; Zixiang Liu; David N Ku
Journal:  APL Bioeng       Date:  2019-11-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.